Earnings Feed
Start Free
CERUS CORP·4/A

Mar 10, 7:05 AM ET

Benjamin Richard J 4/A

Research Summary

AI-generated summary

Updated

Cerus (CERS) CMO Benjamin Richard Sells 125,894 Shares, Receives 55,220 Award

What Happened

  • Benjamin Richard, Chief Medical Officer of Cerus Corp (CERS), received an award of 55,220 shares on March 5, 2026 (acquired at $0.00). Over March 5–9, 2026 he sold a total of 125,894 shares in three transactions, generating aggregate proceeds of approximately $250,931.
  • Sales detail: 61,233 shares on 2026-03-05 at an average price reported as $2.06 ($126,299); 24,235 shares on 2026-03-06 at $2.01 ($48,603); and 40,426 shares on 2026-03-09 at $1.88 ($76,029). The award (55,220 shares) had no cash purchase price recorded in the filing.

Key Details

  • Transaction dates and reported prices:
    • 2026-03-05: Award 55,220 shares @ $0.00 (acquisition)
    • 2026-03-05: Sale 61,233 shares, weighted avg price ~$2.06, proceeds ~$126,299
    • 2026-03-06: Sale 24,235 shares @ ~$2.01, proceeds ~$48,603
    • 2026-03-09: Sale 40,426 shares @ ~$1.88, proceeds ~$76,029
  • Total sold: 125,894 shares for about $250,931; total acquired (award): 55,220 shares.
  • Footnotes in the filing indicate some sales were non‑discretionary: portions were executed under a Rule 10b5‑1 plan and portions were to cover tax withholding tied to vesting; several sales were reported as weighted averages (price ranges or block trade) and the filer offered to provide per‑trade breakdown on request.
  • Filing status: This is an AMENDED Form 4 filed March 10, 2026, covering reportable transactions from March 5–9, 2026. The filing date and amendment are noted in the document; consult the full filing for any previous version or timing details.
  • Shares owned after these transactions are not listed in the information you provided (check the full Form 4 for post‑transaction holdings).

Context

  • Several sales were executed under non‑discretionary arrangements (10b5‑1 and tax‑withholding instructions) — these are routine mechanisms and do not necessarily indicate a change in the insider’s view of the company. The award (55,220 shares) appears to be a grant/vesting event (reported at $0.00 in this filing). For any weighted‑average or block trade prices, the filer states they can provide a per‑trade breakdown to the issuer, shareholders, or SEC staff on request.